Thursday, November 15, 2012

Diagnostic Facts

According to the Personalized Medicine Coalition as of November 2012.

50% of all clinical trials collect DNA from patients to aid in biomarker development.

60% of all treatments in preclinical development rely on biomarker data.

50% of all treatments in early clinical development rely on biomarker data.

30% of all treatments in late clinical development rely on biomarker data.

10% of marketed drugs recommend genetic testing for optimal treatment.

1% of marketed drugs have a companion diagnostic

A total of 33 pharmacogenomic biomarkers are included on FDA-approved drug labels.